Benzinga | Feb 25, 2021 05:28AM EST

Novo Nordisk Invests DKK 500M in Expanding Tablet Production Facilities in Denmark

Novo Nordisk (NYSE:NVO) today announced plans to invest DKK 500 million in expanding facilities at its production site in Mlv, Denmark.

The facility currently manufactures products for oral diabetes treatment and will be expanded to ensure capacity for future production of these products. The project is expected to be completed in 2022.

"This investment in our production facilities in Mlv is an important step in building and ensuring future capacity for production of Rybelsus® (oral semaglutide). Mlv is currently our cornerstone in the production of oral semaglutide, and it is critical that we invest timely in capacity expansion to meet the future demands," said Henrik Steen Jensen, corporate vice president for Novo Nordisk oral semaglutide production.

About Site MlvAt Site Mlv you find our largest research centre together with production facilities for both diabetes and biopharmaceutical products. Our Danish production of oral semaglutide is located at site Mlv and employs currently around 700 people.